Raptor Pharmaceutical to Present at Upcoming Investor Conference

        Print
| Source: Raptor Pharmaceutical Corp.

NOVATO, Calif., Aug. 6, 2013 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that Julie Anne Smith, Raptor's Executive Vice President, Strategy and Chief Operating Officer, will present an overview of the company at the Canaccord Genuity 33rd Annual Growth Conference in Boston. Raptor's presentation will take place on Thursday, August 15, 2013 beginning at 9:30 a.m. EDT/6:30 a.m. PDT.

A live audio webcast and archive of the presentation will be available on the company website at www.raptorpharma.com.

About Raptor Pharmaceutical Corp.

Raptor Pharmaceutical Corp. is a biopharmaceutical company focused on developing and commercializing life-altering therapeutics that treat rare, debilitating and often fatal diseases. The company's first product, PROCYSBI® (cysteamine bitartrate) delayed-release capsules, has been approved by the FDA, and  recommended for marketing authorization by the European Committee for Medicinal Products for Human Use (CHMP) for the management of nephropathic cystinosis, a rare metabolic lysosomal storage disease. Raptor's pipeline also includes RP103 in a Phase 2/3 trial for Huntington's disease and a Phase 2 trial in nonalcoholic fatty liver disease in children. PROCYSBI has orphan designation for nephropathic cystinosis in the U.S. and recommended designation in the EU and RP103 has received U.S. orphan drug designation for Huntington's disease. For additional information, please visit www.raptorpharma.com.

Georgia Erbez
Chief Financial Officer
Raptor Pharmaceutical Corp.
(415) 408-6231


INVESTOR CONTACTS:
Westwicke Partners, LLC
Stefan Loren, Ph.D.
Managing Director
(443) 213-0507


Robert H. Uhl
Managing Director
(858) 356-5932


MEDIA CONTACT:
Carolyn Hawley
Canale Communications
(619) 849-5375